Botox for Migraine: CPT 64615 Pays at 15 Headache Days, Not 14

The short version

• Botox for migraine (CPT 64615, drug J0585) is covered only for chronic migraine, at least 15 headache days a month for more than three months.
• Payers also require documented failure or intolerance of two or more oral prophylactic drug classes, and re-treatment no sooner than about 12 weeks.
• 64615 is billed once per session, bilateral by definition; J0585 units on the claim have to match units given, with JW for the discarded remainder of the vial.
• Episodic migraine, 14 or fewer headache days a month, is not covered, which is the fastest denial in the category.
• The drug is net-even: J0585 is buy-and-bill at about ASP plus six percent, so you make your margin on the 64615 procedure and layered nerve blocks (sphenopalatine 64505, greater and lesser occipital 64405/64450), not on the vial.

Botox for migraine (CPT 64615) is covered at 15 headache days, not 14

Botox for migraine lives or dies on a single number: how many headache days a month.

The International Classification of Headache Disorders defines chronic migraine as at least 15 headache days a month for more than three months, with migraine features on at least 8 of those days. Botox is FDA-approved and payer-covered for chronic migraine only. Episodic migraine, 14 or fewer headache days, is explicitly not covered, and the placebo-controlled trials in episodic patients failed. That’s the whole coverage boundary, and it turns on one day.

Fifteen days pays. Fourteen denies. The reciprocal is brutal in its precision: a patient at 14 documented headache days isn’t a borderline approval, they’re a clean denial, because the diagnosis sits below the chronic threshold. Botox for chronic migraine is a neuromodulator claim, closely related to the blepharospasm and cervical-dystonia work in the same neuromodulator family, and all of them hinge on hitting a documented diagnostic threshold before the drug is billed.

Chronic migraine coverage: 15 days, failed prophylactics, a 12-week clock

Meeting the chronic-migraine definition is necessary but not sufficient. Payers layer a prior-therapy requirement on top.

Most policies require documented failure, intolerance, or contraindication of at least two oral prophylactic drug classes, some want two to three, drawn from beta-blockers, tricyclics like amitriptyline, and anticonvulsants like topiramate or valproate. Re-treatment is covered no sooner than roughly every 12 weeks. Continuation past the first cycles requires a documented response, commonly a reduction of at least seven headache days a month against baseline. Medicare’s LCD on botulinum toxin (L35170) frames the diagnosis and prior-trial expectations, and the American Headache Society commentary on the updated policy tracks how the criteria are read.

The exact count of failed drugs is payer-specific, so read the policy rather than assuming two. (Policy links by code, free: the Medical Necessity tool on Billing IQ.) But the shape is consistent: chronic diagnosis, failed prophylaxis, a 12-week interval, and proof of response to keep going.

64615 bills once; J0585 units have to reconcile to the vial

Two coding facts trip up chronic-migraine Botox claims, and neither is about the diagnosis.

First, 64615 is inherently bilateral and reported once per treatment session, not per muscle, not per side, and never with a bilateral modifier. Report it more than once and you’ve invited an audit. Second, the drug bills separately under J0585, one unit per unit administered. The PREEMPT protocol delivers 155 units across 31 fixed sites, or up to 195 units across 39 with follow-the-pain sites, drawn from a 200-unit vial. If 155 units are used, the 45 discarded units go on a separate line with the JW modifier, and a case with no waste carries JZ. The billed used and wasted units have to add up to the vial.

155 units used, 45 wasted, 200 in the vial. That arithmetic has to close. The reciprocal is a familiar audit trap: units that don’t reconcile to the vial, or a JZ attestation of zero waste on a session that clearly discarded product, is a recoupment waiting to happen.

The drug is net-even; the money is in the procedure

The part that changes how you run the service: the Botox itself isn’t where you make money. J0585 is a buy-and-bill Part B drug reimbursed at roughly ASP plus six percent — after acquisition and handling, the substance is essentially net-even. Expect it to wash. The margin is in the procedure: the 64615 chemodenervation and the services you legitimately layer around it.

That reframes the vial decision. Botox comes in 100- and 200-unit vials, and a 155-unit PREEMPT session from a 200-unit vial leaves 45 units billed as waste on the JW line — real dollars, but on a net-even drug, so it’s recovering cost, not making margin. And the vial interacts with the manufacturer’s buyer program: therapeutic and cosmetic Botox generally accrue to separate reward accounts, so medical volume doesn’t pool with your aesthetic side, and the bigger-vial choice that bills more waste can sit in a different benefit tier than you’d expect. One hard line runs under all of it: you bill the discarded units, you do not resell or reuse them. Wasted means wasted, documented as such.

The procedure itself is modest: 64615 pays about $157 in an office and $109 in a facility in 2026 Medicare national terms, with a greater occipital nerve block (64405) adding roughly $79 more — exactly why the net-even drug and the layered block matter to the economics. These are Medicare national averages; commercial plans, which cover most migraine patients, vary widely, so check your contracts.

Layer the nerve blocks, for necessity and margin

Because the drug is net-even, the peripheral nerve blocks are the layer that pays. The regimen has a map: a sphenopalatine ganglion block (64505) plus greater and lesser occipital blocks (64405 and 64450) — one of each nerve per visit. They’re shorter-acting than the toxin, so they run on their own roughly every-four-week cadence (think visits at weeks 4, 8, and 12 of the cycle), not the ~12-week re-treatment interval the Botox is held to — which means additional billable visits between sessions, not one stacked claim. Clinically they reinforce the medical-necessity story — a comprehensive chronic-migraine program, not a single drug. Financially they’re separately billable procedures that carry real margin, and the SPG block is the higher-value one: about $150 in an office, against roughly $79 for the greater occipital (64405) and $81 for the lesser (64450) — about $310 for the three, or nearer $230 once the same-day multiple-procedure reduction applies (2026 Medicare national; commercial contracts vary, so check yours). And here’s the kicker: the blocks carry no product cost. The anesthetic is pennies, so the block payment is almost pure margin — unlike the toxin, where you float about $1,200 a vial and the reimbursement only washes it back to even. Botox ties up the inventory; the blocks don’t.

The coding has a real limit, and the NCCI edits spell it out: both 64405 and 64505 are edit-paired with 64615, but as modifier-allowed edits — separately reportable with modifier 59 (or XS) when they’re a distinct nerve and site the note supports, not when they collapse into the same anatomical territory as the chemodenervation. Bilateral blocks take modifier 50. Documented as distinct, the blocks are clean added lines on a net-even drug; reflexively appended, they’re an unbundling denial.

Payers re-check the response before the next round of 64615

Getting the first session approved doesn’t lock in the next one.

Continuation of Botox for chronic migraine generally requires documented improvement, commonly a reduction of at least seven headache days a month, or a meaningful drop in severe or migraine days, measured against the pre-treatment baseline. That means the baseline has to be recorded before the first injection and the response tracked after it. A practice that never documents baseline headache days can’t prove the reduction later, and the continuation denial follows.

Track the headache calendar from the start. The response requirement is the payer’s way of confirming the drug is doing something, and the only way to answer it is a number you captured before you began, not one you reconstruct after a denial.

What the chronic-migraine Botox chart needs before you bill 64615

The chronic-migraine Botox denial is usually a documentation gap, and it’s always cheaper to close before the injection than after.

1. Document the chronic-migraine diagnosis. At least 15 headache days a month over three months, with migraine features on 8 or more, coded to the G43.7xx family.
2. Record the failed prophylactics. Two or more oral classes, by name, with the failure, intolerance, or contraindication noted.
3. Reconcile the drug units. J0585 units matching what was given, JW for the discarded remainder of the vial, JZ when there’s none, and 64615 reported once.
4. Capture the baseline for continuation. Headache days before treatment, so you can prove the reduction that keeps coverage going.

The injection technique is standardized; the reimbursement is a documentation discipline built around a headache count and a vial. That’s the kind of pattern our medical billing team puts in front of the claim rather than behind a denial.

Frequently asked questions

This article explains how these codes tend to get paid — it is not coding, billing, or legal advice. Some of the codes here are bundled into the main procedure, or fall into grey areas that vary by payer. Before billing anything in a grey area, confirm it with your own coding and compliance team and the current guidance from the American Headache Society (AHS), Medicare (CMS), and AMA CPT. When in doubt, don’t bill it.